What You Should Know:
– Zephyr AI, Inc. (“Zephyr AI”), a pioneering healthcare technology company announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer (CSO).
– In her new role as CSO, Dr. Brake will spearhead Zephyr AI’s scientific, strategic, and commercial endeavors, leveraging her extensive experience in precision medicine and immuno-oncology.
Dr. Rachael Brake Bio/Background
Before joining Zephyr AI, Dr. Rachael Brake served as the Chief Scientific Officer at Corbus Pharmaceuticals, where she played a pivotal role in building and leading a groundbreaking research and development team focused on precision medicine and immuno-oncology. During her tenure, Dr. Brake successfully delivered two clinical-stage oncology programs and revitalized Corbus’s investment thesis.
Dr. Brake brings over a decade of experience from her tenure at Takeda Oncology, where she held various leadership positions, including Head of U.S. Medical Affairs Oncology and Global Program Vice President. Her contributions at Takeda Oncology encompassed driving translational research initiatives and overseeing medical affairs for oncology products.
“Having spent decades working in big pharma and biotech spanning roles in research, development and commercial, Rachael comes to Zephyr with a unique breadth of experience,” said Jeff Sherman, Zephyr AI Co-Founder, Interim CEO, and Chief Technology Officer. “She is a renowned scientist with an extensive background in oncology and precision medicine and a keen strategist skilled at developing and operationalizing cross-functional teams. Rachael’s mission-driven desire to simplify the complexities of personalized medicine is perfectly aligned with Zephyr’s commitment to address patients’ unmet needs and optimize outcomes.”
